Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma

S.A. and B.G. report receiving honoraria for consulting from Bristol-Myers Squibb. V.M. reports research funding from Roche and Bristol-Myers Squibb. G.V. reports being the main investigator of the AcSé crizotinib trial and Advisory consultant to Bristol Myer Squibb without personal remuneration. L.B. reports being member of an advisory board for Takeda without personal remuneration. The other authors declare no competing interests.